

FORM PTO-1390
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

IMANISHI=2

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/380638

INTERNATIONAL APPLICATION NO.
PCT/JP98/00945INTERNATIONAL FILING DATE
09 March 1998PRIORITY DATE CLAIMED
07 March 1997TITLE OF INVENTION
NOVEL BICYCLONUCLEOSIDE AND OLIGONUCLEOTIDE ANALOGUEAPPLICANT(S) FOR DO/EO/US
Takeshi IMANISHI et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
 1. A courtesy copy of the first page of the International Publication (WO98/39352) in Japanese.
 2. A courtesy copy of the International Search Report.
 3. A courtesy copy of the International Preliminary Examination Report in Japanese.
 4. Formal drawings, 2 sheets, figures 1-2.

09/380638

17. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$970.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$840.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but
international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =**CALCULATIONS** PTO USE ONLY

\$ 840.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	5 - 20 =		X \$18.00
Independent claims	3 - 3 =		X \$78.00

\$

\$

MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$260.00

\$

TOTAL OF ABOVE CALCULATIONS =

\$ 840.00

Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement
must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$

SUBTOTAL =

\$ 840.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$ 840.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$

TOTAL FEES ENCLOSED =

\$ 840.00

Amount to be:

refunded

\$

charged

\$

a. ☒ A check in the amount of \$ 840.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 02-4035. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

BROWDY AND NEIMARK, P.L.L.C.
419 Seventh Street N.W., Suite 300
Washington, D.C. 20004

SIGNATURE:

Norman J. Latker

NAME

19,963

REGISTRATION NUMBER

Date of this submission: September 7, 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit:
Takeshi IMANISHI et al.)
IA No.: PCT/JP98/00945)
IA Filed: March 9, 1998) Washington, D.C.
U.S. App. No.:)
(Not Yet Assigned))
National Filing Date:) September 7, 1999
(Not Yet Received))
For: NOVEL...) Docket No.: IMANISHI=2

PRELIMINARY AMENDMENT

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Prior to examination on the merits, kindly amend as
follows:

IN THE SPECIFICATION

After the title please insert the following paragraph:
--CROSS REFERENCE TO RELATED APPLICATION

The present application is the national stage under 35
U.S.C. 371 of PCT/JP98/00945, filed March 9, 1998. --

Page 4, line 23, replace "alkoxyl" with --alkoxy--;
line 23, delete "and";
line 24, after "group", insert --and an aryloxy
group--; and

In re of IMANISHI=2

lines 24 through 26, delete "The substituent in this case is, for example, a halogen atom, a hydroxyl group, and amino group, an alkoxy group, or an aryloxy group."


REMARKS

The above amendment to the specification is being made to insert reference to the PCT application of which the present case is a U.S. national stage. The present amendment is also being made to place this case into better condition for examination.

Favorable consideration and allowance are earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By 
Norman J. Latker
Registration No. 19,963

NJL:bcs
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
f:\user3\99sep\ima2.pa

510 Rec'd PCT/PTO 07 SEP 1999

SPECIFICATION

NOVEL BICYCLONUCLEOSIDE AND OLIGONUCLEOTIDE ANALOGUE

TECHNICAL FIELD

This invention relates to a novel nucleoside analogue
5 and a novel nucleotide analogue, and more particularly, to a
nucleotide analogue suitable as an antisense molecule.

BACKGROUND ART

In 1978, it was reported for the first time that an
antisense molecule inhibited influenza virus infection.
10 Since then, reports have been issued that antisense
molecules inhibited the expression of oncogenes and AIDS
infection. In recent years, antisense oligonucleotides have
become one of the most promising pharmaceuticals, because
they specifically control the expression of undesirable
15 genes.

The antisense method is based on the idea of
controlling a unidirectional flow called the central dogma,
i.e., DNA → RNA → protein, by use of an antisense
oligonucleotide.

20 When a naturally occurring oligonucleotide was
applied to this method as an antisense molecule, however, it
was decomposed with various nucleases in vivo, or its
permeation through the cell membrane was not high. To solve
these problems, numerous nucleic acid derivatives and
25 analogues have been synthesized, and their studies have been
conducted. Examples of the synthesized products include a
phosphorothioate having a sulfur atom substituting for an
oxygen atom on the phosphorus atom, and a methylphosphonate

having a substituting methyl group. Recently, products have been synthesized in which the phosphorus atom has also been substituted by a carbon atom, or the structure of the sugar portion has been changed, or the nucleic acid base has been modified. Any resulting derivatives or analogues, however, have not been fully satisfactory in terms of in vivo stability, ease of synthesis, and sequence specificity (the property of selectively controlling the expression of a particular gene alone).

Under these circumstances, there has been a demand for the creation of an antisense molecule which is minimally decomposed with a nuclease in vivo, binds to target messenger RNA with high affinity, has high specificity, and can thus efficiently control the expression of a particular gene.

DISCLOSURE OF THE INVENTION

The inventors of the present invention designed a nucleic acid analogue with immobilized conformation of the sugar portion in a nucleic acid, which would be useful in the antisense method. They synthesized a nucleoside analogue which will be a unit structure therefor, and confirmed that an oligonucleotide analogue prepared using it was very useful as an antisense molecule.

BRIEF DESCRIPTION OF THE DRAWINGS


Fig. 1 is a chart showing the time course of the ultraviolet absorption (260 nm) of a naturally occurring oligonucleotide decomposed with an exonuclease; and

Fig. 2 is a chart showing the time course of the

ultraviolet absorption (260 nm) of an oligonucleotide of the present invention (X2) decomposed with an exonuclease.

Details of the present invention will now be described.

5 The structure of a nucleoside analogue according to the present invention is a nucleoside analogue of the following general formula (I)



15 where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, and X and Y are identical or different, and each represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aralkyl group, an aryl group, an
20 acyl group, or a silyl group,
or an amidite derivative thereof.

 The alkyl group represents a straight chain or branched chain alkyl group with 1 to 20 carbon atoms. Its examples include methyl, ethyl, n-propyl, i-propyl, n-butyl,
25 t-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl.

 The alkenyl group represents a straight chain or branched chain alkenyl group with 2 to 20 carbon atoms. Its examples include vinyl, allyl, butenyl, pentenyl, geranyl,

and farnesyl.

The alkynyl group represents a straight chain or branched chain alkynyl group with 2 to 20 carbon atoms. Its examples include ethynyl, propynyl, and butynyl.

5 The cycloalkyl group represents a cycloalkyl group with 3 to 8 carbon atoms, and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Another example is a heterocyclic group in which one or more arbitrary methylene
10 groups on the ring of the cycloalkyl group have been substituted by an oxygen atom, a sulfur atom, or an alkyl-substituted nitrogen atom. It is, for instance, a tetrahydropyranyl group.

15 The aryl group refers to a monovalent substituent formed by removing one hydrogen atom from an aromatic heterocyclic group or an aromatic hydrocarbon group. Preferably, it represents a monovalent substituent formed by removing one hydrogen atom from an aromatic hydrocarbon group, and includes, for example, phenyl, tolyl, xylyl,
20 biphenyl, naphthyl, anthryl, and phenanthryl. The carbon atom on the ring of the aryl group may be substituted by one or more of a halogen atom, a lower alkyl group, a hydroxyl group, an alkoxyl group, an amino group, a nitro group, and a trifluoromethyl group. The substituent in this case is,
25 for example, a halogen atom, a hydroxyl group, an amino group, an alkoxy group, or an aryloxy group.

The aralkyl group refers to an alkyl group bonded to an aryl group, and may be substituted. The aralkyl group

654050" 8E908E60

that may be substituted represents an alkyl group bonded to an aryl group, with one or more arbitrary hydrogen atoms of the aryl group and the alkyl group being optionally substituted by the following substituents: Examples of the

5 substituents are acyl, amino, aryl, alkyl, cycloalkyl, alkoxy, hydroxyl, nitro, and halogen.

The amino group need not be substituted, but the amino group when substituted includes, for example, alkylamino, arylamino, and acylamino. Examples of the

10 alkoxy group are methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, pentyloxy, hexyloxy, and phenoxy. Examples of the halogen atom are fluorine, chlorine, bromine, and iodine.

The preferred examples of the aralkyl group are


15 trityl, benzyl, phenethyl, tritylmethyl, diphenylmethyl, naphthylmethyl, and 4,4'-dimethoxytrityl (DMTr). Particularly preferred is a DMTr group.

As the acyl group, acetyl, formyl, propionyl, benzoyl, and benzyloxycarbonyl can be exemplified. An example of the

20 silyl group is a trialkylsilyl group, preferably trimethylsilyl, triethylsilyl, triisopropylsilyl, t-butyldimethylsilyl or t-butyldiphenylsilyl, and more preferably trimethylsilyl.

The nucleotide analogue of the present invention is

25 an oligonucleotide or polynucleotide analogue having one or more structures of the general formula (Ia)




5

(Ia)

where B is a pyrimidine or purine nucleic acid base,
or an analogue thereof,

or an oligonucleotide or polynucleotide analogue of the
10 general formula (II)



15

(II)


where B¹ and B are identical or different, and each
20 represent a pyrimidine or purine nucleic acid base,
or an analogue thereof, R is a hydrogen atom, a
hydroxyl group, a halogen atom, or an alkoxy group,
W¹ and W² are identical or different, and each
represent a hydrogen atom, an alkyl group, an alkenyl
25 group, an alkynyl group, a cycloalkyl group, an
aralkyl group, an aryl group, an acyl group, a silyl
group, a phosphoric acid residue, a naturally
occurring nucleoside or a synthetic nucleoside bound

via a phosphodiester bond, or an oligonucleotide or polynucleotide containing the nucleoside, n^1 's or n^2 's are identical or different, and each denote an integer of 0 to 50, provided that n^1 's or n^2 's are not zero at the same time, and that not all of n^2 's are zero at the same time, n^3 denotes an integer of 1 to 50, provided that when n^1 and/or n^2 are or is 2 or more, B^1 and B need not be identical, and R's need not be identical.

The pyrimidine or purine nucleic acid base in the present invention refers to thymine, uracil, cytosine, adenine, guanine, or a derivative thereof.

The nucleoside analogue and nucleotide analogue of the present invention can be synthesized in the manner described below.

(1) Synthesis of nucleoside analogue




Compound 1, synthesized from uridine in accordance with the literature [1) J.A. Secrist et al., J. Am. Chem. Soc., 101, 1554 (1979); 2) G.H. Jones et al., J. Org. Chem., 44, 1309 (1979)], was treated with tosyl chloride (TsCl) to
5 tosylate only one of the two primary alcohols, leading to Compound 2. Compound 2 was acid hydrolyzed into a triol compound 3. Compound 3 was condensed with benzaldehyde in the presence of an acid catalyst to form a benzylidene compound 4. Compound 4 was reduced with sodium
10 cyanoborohydride (NaBH_3CN) in the presence of titanium tetrachloride (TiCl_4) to obtain Compound 5. This compound was reacted with sodium hexamethyldisilazide (NaHMDS) in tetrahydrofuran (THF) to obtain a bicyclo compound 6 (Compound I: B = uracil (U), X = H, Y = benzyl). When
15 Compound 6 was catalytically reduced in the presence of a palladium carbon catalyst, a diol compound 7 (Compound (I): B = U, X = Y = H) was obtained. Further treatment of Compound 7 with 4,4'-dimethoxytrityl chloride (DMTrCl) gave a trityl compound 8 (Compound I: B = U, X = DMTr, Y = H).
20 Compounds 6, 7 and 8 can be used as starting materials for various compounds I.

Compounds (I) having various nucleic acid bases, whether natural or nonnatural, other than uridine, can be synthesized by any of the following three methods:

25 The first method is conversion from Compound 8. That is, Compound 8 is acetylated into Compound 9, and then reacted with 1,2,4-triazole to form Compound 10. Hydrolysis of this compound gave Compound 11 (Compound (I): B =

cytosine (C), X = DMTr, Y = H). Compound 12 (Compound (I):
 B = benzoylcytosine (C^{Bz}), X = DMTr, Y = H), which will
 become a starting material for oligonucleotide synthesis,
 can be easily obtained by benzylation of Compound 11.

5



15






The second method is a method performed via Compound
 13 which can be easily obtained from D-ribose in accordance
 with the literature [3) A.G.M. Barrett et al., J. Org. Chem.,
 55, 3853 (1990); 4) G.H. Jones et al., *ibid.*, 44, 1309
 (1979)]. That is, Compound 13 was led to Compound 16 by

20

three steps, and cyclized under basic conditions to obtain a
 desired methylglycosyl compound 17. The OMe group at the 1-
 position of this compound can be substituted by different
 natural nucleic acid bases or nonnatural nucleic acid base
 analogues by various methods which have already been




25

developed. For example, a method as shown by a scheme
 ranging from Compound 17 to Compound 20 can be employed.






The third method starts with diacetone D-glucose, which is obtained from D-glucose by one step and is commercially available. Compound 31 was prepared in accordance with a reference 5) R.D. Youssefyeh, J.P.H.

5 Verheyden and J.G. Moffatt., J. Org. Chem., 44, 1301-1309 (1979). Then, Compound 31 was treated as shown by the following scheme to protect the two primary hydroxyl groups with a t-butyldiphenylsilyl group and a p-toluenesulfonyl group progressively. The protected compound was acetylated into Compound 34.




Compound 34 was condensed, separately, with thymine, benzoyladenine, and isobutyrylguanine activated upon trimethylsilylation (referred to as 2TMS·T, 2TMS·A^{Bz}, and 3TMS·G^{iBu}, respectively), to obtain Compounds 35, 40 and 44 in high yields, as indicated by the scheme offered below. Then, these condensates were subjected to deacetylation

(Compounds 36, 41, 45), five-membered ring formation
 (Compounds 37, 42, 46), desilylation (Compounds 38, 43, 47),
 and further debenzylation to form desired compounds 39.



(2) Synthesis of oligonucleotide analogue

Compound 8 is reacted with 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite to obtain an amidite compound 21. This compound is combined with a naturally occurring nucleoside amidite, and subjected to a DNA synthesizer to synthesize various oligonucleotide analogues. The synthesized crude products are purified using a reversed phase chromatographic column (Oligo-Pak). The purity of the purified product is analyzed by HPLC, whereby the formation of a purified oligonucleotide analogue can be confirmed.



At least one monomer unit as compound 8 can be contained in the oligonucleotide analogue. Alternatively, the monomer units may be present at two or more locations in the oligonucleotide analogue in such a manner as to be separated from each other via one or more naturally occurring nucleotides. The present invention makes it possible to synthesize an antisense molecule incorporating a necessary number of the nucleotide analogues (nucleoside analogues) of the invention (a necessary length of the nucleotide or nucleoside analogue) at a necessary location. The length of the entire oligonucleotide analogue is 2 to 50, preferably 10 to 30, nucleoside units.

Such an oligonucleotide analogue (antisense molecule) is minimally degradable by various nucleases, and can be existent in vivo for a long time after administration. This antisense molecule functions, for example, to form a stable
5 double helix together with a messenger RNA, thereby inhibiting the biosynthesis of a potentially pathogenic protein; or form a triple helix in combination with double-stranded DNA in a genome to inhibit transcription to messenger RNA. The oligonucleotide analogue can also
10 suppress the proliferation of a virus which has infected.

In light of these findings, an oligonucleotide analogue (antisense molecule) using the nucleoside analogue of the present invention is expected to be useful as drugs, including antineoplastics and antivirals, for treatment of
15 diseases by inhibiting the actions of particular genes.

The antisense molecule using the nucleotide (nucleoside) analogue of the present invention can be formulated into parenteral preparations or liposome preparations by incorporating customary auxiliaries such as
20 buffers and/or stabilizers. As preparations for topical application, it may be blended with pharmaceutical carriers in common use to prepare ointments, creams, liquids or plasters.

Synthesis of the nucleoside analogue and nucleotide
25 analogue of the present invention will be described in more detail by way of the following Examples and Production Examples. In these Examples, uracil is mainly used as a base, but other purine nucleic acid bases can also be used

similarly.

[Example 1] Synthesis of nucleoside analogue

(1) Synthesis of 2',3'-O-cyclohexylidene-4'-(p-toluenesulfonyloxymethyl)uridine (Compound 2)

5 To an anhydrous pyridine solution (13.5 ml) of Compound 1 (956 mg, 2.70 mmols) known in the literature, p-toluenesulfonyl chloride (771 mg, 4.05 mmols) was added at room temperature in a stream of nitrogen, and the mixture was stirred for 5 hours at 60°C.

10 To the reaction mixture, a saturated sodium bicarbonate solution was added, whereafter the reaction system was extracted with benzene 3 times. The organic phase was washed once with a saturated sodium chloride solution, and dried over anhydrous MgSO_4 . The solvents were
15 distilled off under reduced pressure, and the residue was subjected to azeotropy with benzene 3 times. The resulting crude product was purified by silica gel column chromatography (CHCl_3 :MeOH = 15:1), and then reprecipitated from benzene-hexane to obtain a white powder (Compound 2)
20 (808 mg, 1.59 mmols, 59%).

Compound 2: White powder, m.p. 104-106°C (benzene-hexane). IR ν (KBr): 3326, 2929, 2850, 1628, 1577, 1544, 1437, 1311, 1244 cm^{-1} . ^1H -NMR (d_6 -acetone): δ 1.45-1.67 (10H, m), 2.45 (3H, s), 3.71 (2H, ABq, J = 12 Hz), 4.20 (2H, ABq, J = 11 Hz), 4.92 (1H, d, J' = 6 Hz), 5.05, 5.06 (1H, dd, J = 4.6 Hz), 5.60 (1H, d, J = 7 Hz), 5.75 (1H, d, J = 4 Hz), 7.48 (2H, d, J = 8 Hz), 7.77 (1H, d, J = 8 Hz), 7.81 (2H, d, J = 8 Hz), 10.10 (1H, s,). ^{13}C -NMR (d_6 -acetone): δ 21.5, 24.1,

24.5, 25.5, 34.8, 36.9, 63.5, 69.7, 82.5, 84.7, 87.8, 92.9,
102.9, 115.4, 128.8, 130.8, 133.9, 142.7, 145.9, 151.3,
163.5. Mass (EI): m/z 481 ($M^+ - H_2O$).

Anal. Calcd. for $C_{23}H_{28}N_2O_9S \cdot 1/3 H_2O$: C, 53.69; H, 5.61;
5 N, 5.44; S, 6.22. Found: C, 53.99; H, 5.48; N, 5.42; S, 6.10.

(2) Synthesis of 4'-(p-toluenesulfonyloxymethyl)uridine
(Compound 3)

The above compound 2 (107 mg, 0.21 mmol) was stirred
in TFA- H_2O (98:2, 1 ml) for 10 minutes at room temperature.

10 The reaction mixture was distilled off under reduced
pressure, and EtOH was added to the residue, followed by
performing azeotropy 3 times. The resulting crude product
was purified by silica gel column chromatography ($CHCl_3$:MeOH
= 10:1) to obtain Compound 3 (85.0 mg, 0.20 mmol, 94%).

15 Compound 3: White powder, m.p. 119-120°C. IR ν
(KBr): 3227, 3060, 2932, 2837, 1709, 1508, 1464, 1252, 978,
835, 763, 556 cm^{-1} . 1H -NMR (d_6 -acetone): δ 2.31 (3H, s), 2.84
(3H, s), 3.71 (2H, s), 4.13, 4.20 (2H, ABq, $J = 11$ Hz), 4.28,
4.31 (1H, dd, $J' = 9.6$ Hz), 4.36 (1H, d, $J' = 6$ Hz), 5.54
20 (1H, d, $J' = 8$ Hz), 5.75 (1H, d, $J = 7$ Hz), 7.32 (2H, d, $J =$
8 Hz), 7.67 (2H, d, $J = 8$ Hz), 7.70 (1H, d, $J' = 8$ Hz),
10.14 (1H, s). ^{13}C -NMR (d_6 -acetone): δ 21.5, 63.7, 70.8, 72.7,
74.6, 86.8, 88.8, 103.1, 128.8, 130.7, 133.9, 141.7, 145.8,
151.8, 163.9. Mass (EI): m/z 256 ($M^+ - OTs$).

25 (3) Synthesis of 2',3'-O-benzylidene-4'-(p-
toluenesulfonyloxymethyl)uridine (Compound 4)

In a stream of nitrogen, benzaldehyde (2.4 ml,
excess) and zinc chloride (670 mg, 5.0 mmols) were added to

the above compound 3 (400 mg, 0.93 mmols), and the mixture was stirred for 5 hours at room temperature. After the reaction was stopped by addition of a saturated sodium bicarbonate solution, the reaction mixture was extracted with chloroform, and washed with a saturated sodium bicarbonate solution, water, and a saturated sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate. The solvents were distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (CHCl_3 :MeOH = 40:1) to obtain Compound 4 (380 mg, 0.74 mmol, 80%).

Compound 4: White powder. m.p. 99-102°C (CH_2Cl_2 -hexane). $[\alpha]_D^{23}$ -26.7° (c = 1.0, CHCl_3). IR ν (KBr): 3059, 1691, 1460, 1362, 1269, 1218, 1177 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 2.41 (3H, s), 3.25 (1H, br), 3.79 (2H, m), 4.19 (2H, s), 5.09 (1H, d, J = 7 Hz), 5.28 (1H, dd, J = 3.7 Hz), 5.60 (1H, d, J = 4 Hz), 5.73 (1H, d, J = 8 Hz), 5.94 (1H, s), 7.24 (1H, d, J = 8 Hz), 7.38 (2H, d, J = 9 Hz), 7.42 (5H, br), 7.69 (2H, d, J = 9 Hz), 9.11 (1H, br). $^{13}\text{C-NMR}$ (CDCl_3): δ 21.6, 63.5, 68.3, 77.2, 82.8, 84.2, 87.7, 94.9, 102.6, 107.5, 126.5, 127.9, 128.5, 129.7, 132.2, 135.0, 143.0, 145.0, 150.4, 163.5.

Anal. Calcd. for $\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_9\text{S} \cdot 1/3 \text{H}_2\text{O}$: C, 55.17; H, 4.76; N, 5.36; S, 6.14. Found: C, 55.19; H, 4.66; N, 5.29; S, 5.98.

(4) Synthesis of 3'-O-benzyl-4'-(p-toluenesulfonyloxymethyl)uridine (Compound 5)

To an acetonitrile solution (3 ml) of Compound 4 (150 mg, 0.29 mmol), sodium borocyanohydride (92 mg, 1.5 mmols)

was added at room temperature in a stream of nitrogen. Then, titanium tetrachloride (0.16 ml, 1.5 mmols) was added dropwise under cooling with ice, and the mixture was stirred for 15 hours at room temperature. The reaction mixture was diluted with chloroform, and washed with a saturated sodium bicarbonate solution, water, and a saturated sodium chloride solution. Then, the organic phase was dried over anhydrous sodium sulfate. After the solvents were distilled off, the residue was purified by silica gel column chromatography (CHCl₃:MeOH = 25:1) to obtain Compound 5 (112 mg, 0.22 mmol, 75%).

Compound 5: Colorless crystals. m.p. 195-197°C (AcOEt-hexane). $[\alpha]_D^{23}$ -14.6° (c = 1.0, CHCl₃). IR ν (KBr): 3033, 2885, 2820, 1726, 1470, 1361, 1274, 1175, 1119 cm⁻¹. ¹H-NMR (CDCl₃) δ : 2.40 (3H, s), 3.59-3.77 (3H, m), 4.10, 4.24 (2H, AB, J = 11 Hz), 4.32 (1H, d, J = 6 Hz), 4.56 (2H, m), 4.69 (1H, d, J = 11 Hz), 5.52 (1H, d, J = 6 Hz), 5.67 (1H, d, J = 8 Hz), 7.24-7.29 (7H, m), 7.48 (1H, d, J = 8 Hz), 7.70 (2H, d, J = 9 Hz), 9.91 (1H, s). ¹³C-NMR (CDCl₃): δ 21.6, 63.2, 69.2, 73.6, 74.6, 78.1, 86.6, 92.9, 102.5, 127.9, 128.2, 128.3, 128.6, 129.9, 132.3, 136.9, 142.4, 145.2, 150.7, 163.8.

Anal. Calcd. for C₂₄H₂₆N₂O₉S: C, 55.59; H, 5.05; N, 5.40; S, 6.18. Found: C, 55.41; H, 5.02; N, 5.32; S, 6.15.

(5) Synthesis of 3'-O-benzyl-2'-O-, 4'-C-methyleneuridine (Compound 6)

To an anhydrous THF solution (1.5 ml) of Compound 5 (80 mg, 0.16 mmol), an anhydrous benzene suspension (0.7 ml)

of NaHMDS (3.2 mmols) was added at room temperature in a stream of nitrogen, and the mixture was stirred for 20 hours at room temperature. A saturated sodium bicarbonate solution was added to the reaction mixture, followed by
5 extracting the mixture with CHCl_3 . The organic phase was washed with a saturated sodium chloride solution, and then dried over anhydrous sodium sulfate. After the solvents were distilled off under reduced pressure, the resulting crude product was purified by silica gel column
10 chromatography (CHCl_3 :MeOH = 10:1), and then recrystallized from MeOH to obtain Compound 6 (41 mg, 0.10 mmol, 61%).

Compound 6: Colorless crystals. m.p. 217-219°C (MeOH). $[\alpha]_D^{23} +108.4^\circ$ (c = 0.3, MeOH). IR ν (KBr): 3059, 2951, 1688, 1459, 1271, 1053 cm^{-1} . $^1\text{H-NMR}$ (d_6 -DMSO) δ : 3.75, 3.85 (2H, AB, J = 8 Hz), 3.77 (2H, d, J = 5 Hz), 3.92 (1H, s), 4.44 (1H, s), 4.60 (2H, s), 5.39 (1H, t, J = 5 Hz), 5.48 (1H, s), 7.31 (5H, m), 7.72 (1H, d, J = 8 Hz), 11.37 (1H, s). $^{13}\text{C-NMR}$ (d_6 -DMSO) δ : 56.0, 71.1, 71.6, 75.8, 76.5, 86.5, 88.3, 100.9, 127.4, 127.6, 128.2, 137.9, 139.0, 150.0, 163.3.
15
20 Mass (EI): m/z 346 (M^+ , 1.1).

Anal. Calcd. for $\text{C}_{17}\text{H}_{18}\text{N}_2\text{O}_6$: C, 58.96; H, 5.24; N, 8.09. Found: C, 58.67; H, 5.23; N, 8.05.

(6) Synthesis of 2'-O,4'-C-methyleneuridine (Compound 7)

To a methanol solution (2.5 ml) of Compound 6 (25 mg, 0.072 mmol), 10% Pd-C (25 mg) was added, and the mixture was stirred for 15 hours at atmospheric pressure in a stream of hydrogen. The reaction mixture was filtered, and the solvent was distilled off. Then, the residue was purified
25

by silica gel column chromatography (CHCl_3 :MeOH = 10:1, then 5:1) to obtain Compound 7 (18.3 mg, quant.).

Compound 7: Colorless crystals. m.p. 239-243°C (MeOH). $[\alpha]_D^{23} +92.2^\circ$ ($c = 0.3$, MeOH). IR ν (KBr): 3331, 3091, 3059, 2961, 1689, 1463, 1272, 1049 cm^{-1} . ^1H -NMR (CD_3OD) δ : 3.76, 3.96 (2H, AB, $J = 8$ Hz), 3.90 (2H, s), 4.04 (1H, s), 4.28 (1H, s), 5.55 (1H, s), 5.69 (1H, d, $J = 8$ Hz), 7.88 (1H, d, $J = 8$ Hz).

Anal. Calcd. for $\text{C}_{10}\text{H}_{12}\text{N}_2\text{O}_6$: C, 46.88; H, 4.72; N, 10.93. Found: C, 46.74; H, 4.70; N, 10.84.

(7) 5'-O-(4,4'-dimethoxytrityl)-2'-O,4'-C-methyleneuridine (Compound 8)

To Compound 7 (140 mg, 0.53 mmol), anhydrous pyridine was added, followed by performing azeotropy of the mixture 3 times. Then, the product was converted into an anhydrous pyridine solution (1.5 ml), and 4,4'-dimethoxytrityl chloride (210 mg, 0.63 mmol) and DMAP (6.5 mg, 0.053 mmol) were added at room temperature in a stream of nitrogen. The mixture was stirred for 5 hours at room temperature. To the reaction mixture, a saturated sodium bicarbonate solution was added, followed by extraction with CH_2Cl_2 . The organic phase was washed with water and a saturated sodium chloride solution, and then dried over anhydrous sodium sulfate. After the solvents were distilled off under reduced pressure, the resulting crude product was purified by silica gel column chromatography (CHCl_3 :MeOH = 40:1) to obtain Compound 8 (230 mg, 0.34 mmol, 66%).

Compound 8: White powder. m.p. 117-120°C (CHCl_3).

662060" BE908E50

$[\alpha]_D^{23} + 17.2^\circ$ ($c = 1.0$, CHCl_3). IR ν (KBr): 3393, 3101, 2885, 1689, 1464, 1272, 1047 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3) δ : 2.59 (1H, br), 3.56 (2H, q, $J = 7, 11$ Hz), 3.87 (1H, d, $J = 7$ Hz), 4.26 (1H, s), 4.47 (1H, s), 5.60 (1H, d, $J = 9$ Hz), 5.63 (1H, s), 5.84 (4H, d, $J = 9$ Hz), 7.22-7.45 (9H, m), 7.93 (1H, d, $J = 9$ Hz).

[Example 2] Synthesis of nucleoside analogue

(1) Synthesis of methyl-5-O-(*t*-butyldiphenylsilyl)-4-hydroxymethyl-2,3-O-isopropylidene- β -D-ribofuranoside (Compound 14)

10 In a stream of nitrogen, Et_3N (2.62 ml, 18.8 mmols) and *t*-butyldiphenylsilyl chloride (4.88 ml, 18.8 mmols) were added to an anhydrous CH_2Cl_2 solution (40 ml) of Compound 13 (2.00 g, 8.54 mmols) known in the literature under cooling with ice, and the mixture was stirred for 13 hours at room

15 temperature. To the reaction mixture, a saturated sodium bicarbonate solution was added, whereafter the reaction system was extracted with AcOEt 3 times. The organic phase was washed once with a saturated sodium chloride solution, and then dried over anhydrous Na_2SO_4 . The solvents were

20 distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt = 5:1) to obtain colorless oily matter (Compound 14) (2.82 g, 5.98 mmols, 70%).

$[\alpha]_D^{17} - 16.2^\circ$ ($c = 0.52$, CHCl_3). IR ν (KBr): 3510, 3061, 2938, 2852, 1465, 1103 cm^{-1} .

$^1\text{H-NMR}$ (CDCl_3) δ : 1.09 (9H, s), 1.28 (3H, s), 1.49 (3H, s), 3.22 (3H, s), 3.67, 3.76 (2H, AB, $J = 11$ Hz), 3.88, 3.93 (2H, AB, $J = 11$ Hz), 4.49 (1H, d, $J = 6$ Hz), 4.57 (1H, d, $J = 6$

Hz), 4.93 (1H, s), 7.38 - 7.43 (6H, m), 7.67 (4H, d, J = 7 Hz).

^{13}C -NMR (CDCl_3) δ_c : 19.2, 24.4, 25.9, 26.9, 55.0, 62.9, 64.8, 82.2, 85.9, 88.7, 108.6, 112.6, 127.8, 129.9, 133.0, 135.7.

5 Anal. Calcd. for $\text{C}_{26}\text{H}_{36}\text{O}_6\text{Si} \cdot 1/4 \text{H}_2\text{O}$: C, 65.45; H, 7.71. Found: C, 65.43; H, 7.59.

(2) Synthesis of methyl-5-O-(t-butyldiphenylsilyl)-2,3-O-isopropylidene-4-(p-toluenesulfonyloxymethyl)- β -ribofuranoside (Compound 15)

10 In a stream of nitrogen, Et_3N (3.92 g, 28.0 mmols), p-toluenesulfonyl chloride (1.34 g, 7.22 mmols), and 4-dimethylaminopyridine (90 mg, 0.72 mmol) were added to an anhydrous CH_2Cl_2 solution (15 ml) of Compound 14 (2.13 g, 4.51 mmols), and the mixture was stirred for 17 hours at
15 room temperature. To the reaction mixture, a saturated sodium bicarbonate solution was added, whereafter the reaction system was extracted with AcOEt 3 times. The organic phase was washed once with a saturated sodium chloride solution, and then dried over anhydrous Na_2SO_4 . The
20 solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt = 10:1) to obtain colorless oily matter, Compound 15 (2.76 g, 4.42 mmols, 98%). $[\alpha]_D^{17}$ -3.82° (c = 0.56, CHCl_3). IR ν (KBr): 2934, 2852, 1369, 1104
25 cm^{-1} .

^1H -NMR (CDCl_3) δ : 1.02 (9H, s), 1.20 (3H, s), 1.32 (3H, s), 2.41 (3H, s), 3.09 (3H, s), 3.51, 3.77 (2H, AB, J = 10 Hz), 4.34 (1H, d, J = 6 Hz), 4.25, 4.39 (2H, AB, J = 9 Hz), 4.47

(1H, d, J = 6 Hz), 4.77 (1H, s), 7.28, 7.81 (4H, AB, J = 9 Hz), 7.39 - 7.44 (6H, m), 7.62 - 7.65 (4H, m), 7.81 (2H, d, J = 9 Hz).

¹³C-NMR (CDCl₃) δ_c: 19.2, 21.6, 24.5, 25.8, 26.8, 54.9, 62.7, 68.8, 81.9, 85.6, 87.5, 108.7, 112.8, 127.7, 127.8, 128.2, 129.6, 129.9, 132.9, 135.6, 144.4.

Anal. Calcd. for C₃₃H₄₂O₈SSi: C, 63.23; H, 6.75; S, 5.11.

Found: C, 62.99; H, 6.53; S, 5.13.

(3) Synthesis of methyl=5-O-(t-butyl diphenylsilyl)-4-(p-toluenesulfonyloxymethyl)-β-D-ribofuranoside
(Compound 16)

Trifluoroacetic acid (14 ml) was added to a THF-H₂O [11 ml, 8:3 (v/v)] solution of Compound 15 (645 mg, 1.03 mmol) at room temperature, and the mixture was stirred for 20 minutes at room temperature. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt = 5:1) to obtain colorless oily matter, Compound 16 (464 mg, 0.79 mmol, 77%). [α]_D¹⁷ -35.8° (c=1.90, CHCl₃) IR ν (KBr): 3499, 3051, 2931, 2840, 1594, 1468, 1362, 1109 cm⁻¹.

¹H-NMR (CDCl₃) δ: 1.02 (9H, s), 2.42 (3H, s), 3.16 (3H, s), 3.54, 3.70 (2H, AB, J=10 Hz), 3.97 (1H, d, J=5 Hz), 4.18 (1H, d, J=5 Hz), 4.26, 4.39 (2H, AB, J=10 Hz), 4.73 (1H, s), 7.30 (2H, d, J=8 Hz), 7.36-7.44 (6H, m), 7.59-7.66 (4H, m), 7.78 (2H, d, J=8 Hz). ¹³C-NMR (CDCl₃) δ_c: 19.2, 21.6, 26.7, 55.2, 66.5, 69.6, 74.0, 75.2, 76.5, 84.8, 107.5, 127.7, 128.0, 129.8, 132.6, 132.7, 132.8, 135.5, 135.6, 144.9.

Anal. Calcd for C₃₀H₃₈SSiO₈·1/4 H₂O: C, 60.94; H, 6.56. Found: C,

60.94; H, 6.43.

(4) Synthesis of methyl=5-O-(t-butyldiphenylsilyl)-2-O,4-C-methylene- β -D-ribofuranoside (Compound 17) and methyl=5-O-(t-butyldiphenylsilyl)-3-O,4-C-methylene- β -D-ribofuranoside (Compound 18)

In a stream of nitrogen, a benzene suspension (1.6 ml) of NaHMDS (3.30 mmols) was added to an anhydrous THF solution (4 ml) of Compound 16 (194 mg, 0.33 mmol) at room temperature, and the mixture was stirred for 1 hour at room temperature. After a saturated sodium bicarbonate solution was added to the reaction mixture, the reaction solvents were distilled off, and the residue was extracted with AcOEt 3 times. The organic phase was washed once with a saturated sodium chloride solution, and then dried over anhydrous Na₂SO₄. The solvent was distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt = 5:1) to obtain colorless oily matter, Compound 17 (48 mg, 0.116 mmol, 35%) and colorless oily matter, Compound 18 (59 mg, 0.142 mmol, 43%).

Compound 17: IR ν (KBr): 3438, 3064, 1103, 1036 cm⁻¹.

¹H-NMR (CDCl₃) δ : 1.08(9H, s), 2.04(1H, br s), 3.39(3H, s), 3.65, 3.98(2H, AB, J=8Hz), 3.95, 4.02(2H, AB, J=12Hz), 4.02(1H, s), 4.30(1H, s), 4.79(1H, s), 7.38-7.46(6H, m), 7.65-7.69(4H, m).

¹³C-NMR (CDCl₃) δ : 19.2, 26.7, 55.0, 60.7, 71.2, 73.1, 79.9, 85.5, 104.3, 127.8, 129.9, 130.0, 132.9, 135.6, 135.7.

Anal. Calcd for C₂₃H₃₀O₅Si·1/4 H₂O: C, 65.68; H, 7.34. Found: C, 65.98; H, 7.23.

Compound 18: IR ν (KBr): 3456, 3058, 2938, 2852, 1467, 1108 cm^{-1} .

^1H -NMR (CDCl_3) δ : 1.10 (9H, s), 3.26 (3H, s), 3.71 (2H, s), 4.02 (1H, d, $J=6\text{Hz}$), 4.35, 4.95 (2H, d, $J=7\text{Hz}$), 5.01 (1H, s), 5.11 (1H, d, $J=6\text{Hz}$), 7.38-7.44 (6H, m), 7.66 (4H, d, $J=7\text{Hz}$).

^{13}C -NMR (CDCl_3) δ_c : 19.3, 26.8, 55.4, 63.7, 75.1, 77.9, 84.5, 86.3, 111.9, 127.8, 128.0, 129.9, 132.9, 133.0, 135.6, 135.8, 135.9.

Anal. Calcd for $\text{C}_{23}\text{H}_{30}\text{O}_5\text{Si} \cdot 1/4 \text{H}_2\text{O}$: C, 65.91; H, 7.34. Found: C, 66.07; H, 7.14.

(5) Synthesis of methyl=3-O-acetyl-5-O-(*t*-butyldiphenylsilyl)-2-O,4-C-methylene- β -D-ribofuranoside (Compound 19)

In a stream of nitrogen, acetic anhydride (0.38 ml, 4.08 mmols) and 4-dimethylaminopyridine (21 mg, 0.170 mmols) were added to an anhydrous pyridine solution (10 ml) of Compound 17 (704 mg, 1.70 mmols) at room temperature, and the mixture was stirred for 3 hours at room temperature. After a saturated sodium bicarbonate solution was added to the reaction mixture, the system was extracted with AcOEt 3 times. The organic phase was washed once with a saturated sodium chloride solution, and then dried over anhydrous Na_2SO_4 . The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt = 7:1) to obtain colorless oily matter, Compound 19 (665 mg, 1.46 mmols, 86%).

$[\alpha]_D^{17} -34.3^\circ$ ($c=0.93, \text{CHCl}_3$) IR ν (KBr): 3438, 3064, 2934, 1749,

1468, 1103, 1036 cm^{-1} .

^1H -NMR (CDCl_3) δ : 0.99(9H,s), 1.97(3H,s), 3.34(3H,s), 3.69, 3.86(2H,AB,J=8Hz), 3.86(2H,s), 4.17(1H,s), 4.77(1H,s), 5.06 (1H,s), 7.28-7.39(6H,m), 7.58-7.63(4H,m).

5 ^{13}C -NMR(CDCl_3) δ_c : 19.3, 20.9, 26.7, 55.0, 60.3, 72.0, 73.6, 78.3, 85.3, 104.4, 127.7, 129.8, 133.0, 135.6, 169.8.

Anal.Calcd for $\text{C}_{25}\text{H}_{32}\text{O}_6\text{Si}\cdot 1/4 \text{H}_2\text{O}$:C,65.12; H,7.10. Found:C, 65.27;H,7.00.

(6) Synthesis of 5'-O-(t-butyldiphenylsilyl)-2'-O,4'-C-methylene-5-methyluridine (Compound 20)

In a stream of nitrogen, O,O'-bistrimethylsilylthymine (154 mg, 0.598 mmols) was added to an anhydrous CH_3CN solution (2 ml) of Compound 19 (109.2 g, 0.239 mmol) at room temperature. Then, a 1,1-dichloroethane
15 (0.31 ml) solution of trimethylsilyltrifluoromethane sulfonate (0.82 ml, 8.74 mmols) was added under cooling with ice, and the mixture was stirred for 18 hours at room temperature. The reaction mixture was diluted with CH_2Cl_2 , and a saturated sodium bicarbonate solution was added,
20 followed by extracting the system with AcOEt 3 times. The organic phase was washed once with a saturated sodium chloride solution, and then dried over anhydrous Na_2SO_4 . The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column
25 chromatography (hexane:AcOEt = 3:1) to obtain colorless oily matter, Compound 20 (87.7 mg, 0.173 mmol, 70%).

IR ν (KBr):3048, 2935, 2852, 1749, 1466, 1369, 1234, 1108, 1040 cm^{-1} .

¹H-NMR (CDCl₃)δ: 1.06(9H,s), 1.94(3H,s), 2.98(1H,br s), 3.63, 4.00(2H,AB,J=10Hz), 3.72(1H,d,J=7Hz), 3.82-3.84(2H,m), 4.30 (1H,s), 5.25(1H,s), 7.40-7.46(6H,m), 7.60(4H,d,J=6Hz), 7.66 (1H,s), 9.68(1H,br s).

5 [Example 3] Synthesis of nucleoside analogue (different method)

(1) Synthesis of 3-O-benzyl-5-O-t-butyldiphenylsilyl-4-(hydroxymethyl)-1,2-O-isopropylidene-α-D-erythropentofuranose (Compound 32)

10 In a stream of nitrogen, triethylamine (3.71 ml, 26.6 mmols) and t-butyldiphenylsilyl chloride (6.94 ml, 26.7 mmols) were added, under cooling with ice, to a methylene chloride solution (50 ml) of Compound 31 (2.50 g, 8.08 mmols) prepared in accordance with the aforementioned

15 reference 5). The mixture was stirred for 10.5 hours at room temperature. After a saturated sodium bicarbonate solution was added to the reaction mixture, the system was extracted with ethyl acetate. The organic phase was washed with a saturated sodium chloride solution, and then dried

20 over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane: = 1:4 → 1:3) to obtain a white solid, Compound 32 (2.97 g, 5.41 mmols, 67%).

25 m.p. 98-99°C (hexane). $[\alpha]_D^{20} + 54.8^\circ$ (c = 1.12, acetone).

IR ν max (KBr) : 3553, 2936, 1463, 1379, 1107 cm⁻¹.

¹H-NMR(CDCl₃)δ: 1.13 (9H, s), 1.50 (3H, s), 1.78 (3H, s), 2.56 (1H, t, J = 7 Hz), 3.82, 3.92 (2H, AB, J = 11 Hz), 3.94 (2H, t,

5 J = 6 Hz), 4.57 (1H, d, J = 5 Hz), 4.64, 4.95 (2H, AB, J = 12 Hz), 4.83 (1H, dd, J = 4, 5 Hz), 5.95 (1H, d, J = 4 Hz), 7.44-7.55 (11H, m), 7.72-7.78 (4H, m). ¹³C-NMR(CDCl₃)δ_c: 19.2, 26.2, 26.5, 26.8, 63.2, 65.4, 72.5, 77.9, 79.1, 87.4, 104.4, 113.7, 127.6, 127.7, 128.0, 128.5, 129.5, 129.7, 132.9, 133.1, 134.7, 135.5, 137.2.

Anal. Calcd for C₃₂H₄₀O₆Si : C, 70.04; H, 7.38. Found : C, 70.19; H, 7.35.

664060" 02908660
10 (2) Synthesis of 3-O-benzyl-5-O-(t-butyldiphenylsilyl)-4-(p-toluenesulfonyloxymethyl)-1,2-α-D-erythropentofuranose (Compound 33)

In a stream of nitrogen, triethylamine (395 μl, 2.83 mmols), p-toluenesulfonyl chloride (139.2 mg, 0.730 mmol), and 4-dimethylaminopyridine (8.92 mg, 0.0730 mmols) were
15 added, under cooling with ice, to a methylene chloride solution of Compound 32 (250 mg, 0.456 mmol). The mixture was stirred for 15.5 hours at room temperature. After a saturated sodium bicarbonate solution was added to the reaction mixture, the system was extracted with ethyl
20 acetate. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane: = 1:6) to obtain light
25 yellow oily matter, Compound 33 (310.6 mg, 0.442 mmol, 97%). [α]_D²⁰+16.0° (c = 0.44, acetone). IR ν max (KBr) : 2935, 1595, 1462, 1363, 1174, 1106 cm⁻¹.

¹H-NMR(CDCl₃)δ: 1.08 (9H, s), 1.40 (3H, s), 1.46 (3H, s), 2.48

(3H, s), 3.68, 3.83 (2H, AB, J = 11 Hz), 4.45 (2H, dd, J = 4, 5 Hz), 4.64, 4.81 (2H, AB, J = 12 Hz), 4.68 (1H, dd, J = 4, 5 Hz), 5.81 (1H, d, J = 4 Hz), 7.32 (2H, d, J = 8 Hz), 7.42-7.72 (15H, m), 7.82, (2H, d, J = 8 Hz), 7.66 (4H, m), 7.72 (2H, d, J = 8 Hz).

$^{13}\text{C-NMR}(\text{CDCl}_3)\delta_c$: 19.1, 21.5, 26.1, 26.4, 26.7, 64.4, 70.0, 72.5, 78.1, 78.9, 85.4, 104.2, 113.6, 127.3, 127.7, 127.9, 128.0, 128.4, 129.6, 129.7, 129.8, 132.7, 132.8, 135.5, 137.2, 144.4. MS(EI) m/z : 646 ($\text{M}^+ - \text{t-Bu}$). High-MS(EI):

10 Calcd for $\text{C}_{35}\text{H}_{37}\text{O}_8\text{SSi}$ ($\text{M}^+ - \text{t-Bu}$) : 645.1978, Found : 645.1969.

(3) Synthesis of 1,2-di-O-acetyl-3-O-benzyl-5-O-t-butyl-diphenylsilyl-4-(p-toluenesulfonyloxymethyl)- α - and - β -D-ribofuranose (Compound 34)

In a stream of nitrogen, acetic anhydride (6.0 ml, 63.6 mmols) and concentrated sulfuric acid (56 μl , 1.10 μmol) were added to an acetic acid solution (56 ml) of Compound 34 (3.70 g, 5.27 mmols). The mixture was stirred for 2 hours at room temperature. The reaction mixture was emptied into iced water (300 ml), and stirred for 30 minutes. After a saturated sodium chloride solution was added, the mixture was extracted with ethyl acetate. Then, the organic phase was dried over magnesium sulfate. The solvents were distilled off, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane, 2:1) to obtain yellow oily matter, Compound 34 (3.36 g, 4.53 mmols, 86%), as an α - β (1:4) mixture.

IR ν_{max} (KBr) : 2934, 2863, 1751, 1365, 1217, 1106 cm^{-1} .

$^1\text{H-NMR}(\text{CDCl}_3)$ [β -configuration] δ : 1.02 (9H, s), 1.77 (3H, s),

1.98 (3H, s), 2.39 (3H, s), 3.61, 3.76 (2H, AB, J = 11 Hz),
4.21-4.58 (5H, m), 5.26 (1H, d, J = 5 Hz), 5.94 (1H, s), 7.15-
7.59 (13H, m), 7.58-7.66 (4H, m), 7.72 (2H, d, J = 8 Hz). [α -
configuration] d: 1.02 (9H, s), 1.98 (3H, s), 2.36 (3H, s),
5 3.48, 3.58 (2H, AB, J = 11 Hz), 4.21-4.58 (5H, m), 5.12 (1H,
dd, J = 5, 6 Hz), 6.33 (1H, d, J = 5 Hz), 7.15-7.59 (13H, m),
7.58-7.66 (4H, m), 7.72 (2H, d, J = 8 Hz).

^{13}C -NMR (CDCl_3) δ_c : 14.2, 19.3, 20.5, 20.8, 21.6, 26.7, 26.8,
60.3, 64.8, 69.1, 73.6, 74.1, 78.6, 85.3, 97.4, 127.4, 127.6,
10 127.7, 127.8, 127.9, 128.0, 128.2, 128.3, 128.4, 129.5,
129.6, 1289.8, 129.9, 132.4, 132.8, 132.9, 135.4, 135.5,
135.6, 136.9, 144.5, 168.7, 169.4. High-MS(FAB) :

Calcd for $\text{C}_{40}\text{H}_{46}\text{N}_2\text{O}_{10}\text{SSiNa}$ ($\text{M}^+ + \text{Na}$) : 769.2479, Found : 769.2484.

(4) Synthesis of 2'-O-acetyl-3'-O-benzyl-5'-O-t-
15 butyldiphenylsilyl-4'-p-toluenesulfonyloxymethyl-5-
methyluridine (Compound 35)

In a stream of nitrogen, 2TMS·T (1.04 g, 4.03 mmols)
and trimethylsilyltrifluoromethane sulfonate (730 μl , 4.03
mmols) were added, under cooling with ice, to a 1,2-
20 dichloroethane solution (26 ml) of Compound 34 (1.88 g, 2.52
mmols), and the mixture was stirred for 17 hours at room
temperature. A saturated sodium bicarbonate solution was
added to the reaction mixture, and the system was filtered
through Celite, followed by extracting the mother liquor
25 with chloroform. The organic phase was washed with a
saturated sodium chloride solution, and then dried over
sodium sulfate. The solvents were distilled off under
reduced pressure, and the resulting crude product was

purified by silica gel column chromatography (AcOEt-hexane, 2:3) to obtain a white powder, Compound 35 (2.00 g, 2.44 mmols, 97%).

m.p. 70-71.5°C. $[\alpha]_D^{24} + 4.58^\circ$ (c = 1.25, acetone).

5 IR ν max (KBr) : 3059, 2934, 1694, 1465, 1368, 704 cm^{-1} .

$^1\text{H-NMR}(\text{CDCl}_3)\delta$: 1.18 (9H, s), 1.63 (3H, d, J = 1 Hz), 2.10 (3H, s), 2.42 (3H, s), 3.73, 3.86 (2H, AB, J = 11 Hz), 4.12, 4.20 (2H, AB, J = 11 Hz), 4.44, 4.57 (2H, AB, J = 11 Hz), 4.45 (1H, d, J = 6 Hz), 5.38 (1H, t, J = 6 Hz), 6.02 (1H, d, J = 6 Hz),

10 7.21-7.60 (13H, m), 7.62-7.69 (7H, m), 8.91 (1H, br s).

$^{13}\text{C-NMR}(\text{CDCl}_3)\delta_c$: 11.9, 19.3, 20.6, 21.6, 27.0, 65.3, 68.6, 74.1, 74.8, 77.2, 77.3, 86.0, 86.4, 111.6, 127.9, 128.0, 128.2, 128.5, 129.7, 130.1, 130.2, 131.8, 132.3, 132.5, 135.3, 135.5, 135.6, 136.8, 144.9, 150.2, 163.4, 170.2. MS (FAB) m/z

15 : 813 ($\text{M}^+ + \text{H}$).

Anal. Calcd for $\text{C}_{43}\text{H}_{48}\text{N}_2\text{O}_{10}\text{SSi} \cdot 2\text{H}_2\text{O}$: C, 60.83; H, 6.17; N, 3.30.

Found : C, 60.55; H, 5.78; N, 3.22.

(5) Synthesis of 3'-O-benzyl-5'-O-t-butylldiphenylsilyl-4'-p-toluenesulfonyloxymethyl-5-methyluridine

20 (Compound 36)

Potassium carbonate (12.75 mg, 0.0923 mmol) and water (0.5 ml) were added, under cooling with ice, to a methyl alcohol solution (4 ml) of Compound 35 (250 mg, 0.308 mmol), and the mixture was stirred for 22 hours at room temperature.

25 Under cooling with ice, acetic acid was added to the reaction mixture to neutralize it, whereafter the solvent was distilled off under reduced pressure. After water was added to the residue, the mixture was extracted with ethyl

acetate. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvent was distilled off under reduced pressure, and then the resulting crude product was purified by silica gel
5 column chromatography (AcOEt-hexane, 3:2) to obtain a white powder, Compound 36 (216.7 mg, 0.283 mmol, 92%).

mp. 74 - 77°C. $[\alpha]_D^{23} + 5.15^\circ$ (c = 1.23, CHCl₃). IR ν max (KBr) : 3048, 2934, 1695, 1363, 1181, 1108, 977, 819, 704 cm⁻¹.

¹H-NMR (CDCl₃) δ : 1.05 (9H, s), 1.65 (3H, d, J = 1 Hz), 2.39
10 (3H, s), 3.04 (1H, br d, J = 9 Hz), 3.72 (2H, s), 4.17 (2H, s), 4.18 (1H, d, J = 5 Hz), 4.24-4.32 (1H, m), 4.54, 4.62 (2H, AB, J = 11 Hz), 5.62 (1H, d, J = 6 Hz), 7.19-7.69 (20H, m), 8.46 (1H, br s).

¹³C-NMR (CDCl₃) δ_c : 12.1, 19.4, 26.9, 58.8, 72.0, 72.2, 75.8,
15 76.7, 87.4, 88.8, 110.4, 127.7, 127.9, 128.1, 128.2, 128.5, 128.7, 129.8, 130.0, 130.1, 132.2, 134.3, 135.3, 135.5, 136.8, 149.8, 163.9. MS(FAB) m/z : 771 (M⁺+H).

Anal. Calcd for C₄₁H₄₆N₂O₉SSi: C, 63.41; H, 6.16; N, 3.51; S, 3.95.

20 Found : C, 63.87; H, 6.01; N, 3.63; S, 4.16.

(6) Synthesis of 3'-O-benzyl-5'-O-t-butyldiphenylsilyl-
2'-O,4'-C-methylene-5-methyluridine (Compound 37)

In a stream of nitrogen, sodium
bis(trimethylsilyl)amide (1.0 M in THF, 8.47 ml, 8.47 mmols)
25 was added, under cooling with ice, to a tetrahydrofuran solution (30 ml) of Compound 36 (1.86 g, 2.42 mmols), and the mixture was stirred for 1 hour at room temperature. A saturated sodium bicarbonate solution (14 ml) was added to

the reaction mixture, and then the solvent was distilled off under reduced pressure. After water was added to the residue, the mixture was extracted with chloroform. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane, 2:3) to obtain a white powder, Compound 37 (1.42 g, 2.37 mmols, 98%).

m.p. 70.5-72°C. $[\alpha]_D^{22} + 52.47^\circ$ (c = 1.025, acetone). IR ν max (KBr) : 2936, 1694, 1465, 1275, 1106, 1055, 809, 704 cm^{-1} .

$^1\text{H-NMR}$ (CDCl_3) δ : 1.21 (9H, s), 1.76 (3H, s), 3.88, 4.07 (2H, AB, J = 8 Hz), 4.07, 4.15 (2H, AB, J = 11 Hz), 4.16 (1H, s), 4.66, 4.80 (2H, AB, J = 11 Hz), 4.76 (1H, s), 7.34-7.79 (16H, m), 10.0 (1H, br s). MS (FAB) m/z : 599 ($\text{M}^+ + \text{H}$).

Anal. Calcd for $\text{C}_{34}\text{H}_{38}\text{N}_2\text{O}_6\text{Si} \cdot 2\text{H}_2\text{O}$: C, 64.33; H, 6.03; N, 4.41. Found : C, 64.58; H, 6.15; N, 4.28.

(7) Synthesis of 3'-O-benzyl-2'-O,4'-C-methylene-5-methyluridine (Compound 38)

In a stream of nitrogen, tetrabutylammonium fluoride (1.0 M in THF, 379 μl , 0.379 μmol) was added to a tetrahydrofuran solution (1 ml) of Compound 37 (188.7 mg, 0.316 mmol), and the mixture was stirred for 2.5 hours at room temperature. The reaction mixture was distilled under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane, 1:1 \rightarrow 1:0) to obtain a white powder, Compound 38 (94.6 mg, 0.262 mmol, 83%).

IR ν max (KBr) : 3424, 3183, 3063, 2950, 1691, 1463, 1273, 1057, 734 cm^{-1} .

^1H -NMR (CDCl_3) δ : 1.90(3H, d, J = 1 Hz), 3.83, 4.05(2H, AB, J = 8 Hz), 3.93, 4.02(2H, AB, J = 12 Hz), 3.94(1H, s), 4.53(1H, s), 4.56, 4.58(2H, AB, J = 12 Hz), 5.65 (1H, s), 7.32(5H, s), 7.44(1H, d, J = 1 Hz). High-MS (EI):

Calcd for $\text{C}_{18}\text{H}_{20}\text{NO}_6$ (M^+) : 360.1321, Found : 360.1312.

(8) Synthesis of 2'-O,4'-C-methylene-5-methyluridine
(Compound 39a)

To a methyl alcohol solution (4 ml) of Compound 38 (86.5 mg, 0.240 mmol), 20% $\text{Pd}(\text{OH})_2\text{-C}$ (86.5 mg) was added, and the mixture was stirred for 14.5 hours at atmospheric pressure in a stream of hydrogen. The reaction mixture was filtered, and then the solvent was distilled off under reduced pressure to obtain colorless crystals, Compound 39 (62.5 mg, 0.230 mmol, 96%).
mp. 194-195°C. $[\alpha]_D^{20} + 53.7^\circ$ (c = 1.02, EtOH). IR ν max (KBr) : 3323, 3163, 3027, 2889, 2826, 1689, 1471, 1276, 1057 cm^{-1} .

^1H -NMR (CD_3OD) δ : 1.89 (3H, q, J = 1 Hz), 3.74, 3.95 (2H, AB, J = 8 Hz), 3.90 (1H, s), 4.07 (1H, s), 4.26 (1H, s), 5.53 (1H, s), 7.74 (1H, d, J = 1 Hz).

^{13}C -NMR (CD_3OD) δ c: 12.6, 57.6, 70.3, 72.4, 80.8, 88.3, 90.4, 110.7, 136.8, 151.8, 166.5.

[Example 4]

(1) Synthesis of 2'-O-acetyl-3'-O-benzyl-5'-O-t-butyl-
diphenylsilyl-4'-p-toluenesulfonyloxymethyl- N^6 -
benzoyladenine (Compound 40)

662060" BE903E62

In a stream of nitrogen, a 1,2-dichloroethane solution (5.0 ml) of Compound 34 (250 mg, 0.336 mmol) and trimethylsilyltrifluoromethane sulfonate (6.7 μ l, 0.0336 mmols) were added, at room temperature, to 2TMS \cdot A^{Bz} (128.7 mg, 0.336 mmol) prepared in accordance with a reference 6) (H. Vorbruggen, K. Krolikiewicz and B. Bennua, Chem., Ber., 114, 1234-1255 (1981)). The mixture was heated under reflux for 26 hours. After a saturated sodium bicarbonate solution was added to the reaction mixture, the system was extracted 3 times with methylene chloride. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl₃-MeOH, 1:3) to obtain a white powder, Compound 40 (234.5 mg, 0.253 mmol, 75%).

m.p. 77-78°C (AcOEt/hexane). $[\alpha]_D^{24}$ - 13.2° (c = 1.00, CHCl₃). IR ν max (KBr): 3058, 2934, 1749, 1703, 1606, 1105 cm⁻¹. ¹H-NMR (CDCl₃) δ : 0.99 (9H, s), 2.04 (3H, s), 2.38 (3H, s), 3.74, 3.85 (2H, AB, J = 11 Hz), 4.31, 4.43 (2H, AB, J = 11 Hz), 4.52, 4.58 (2H, AB, J = 11 Hz), 4.81 (1H, d, J = 6 Hz), 5.94 (1H, d, J = 6 Hz), 6.04 (1H, d, J = 5 Hz), 7.18 - 7.61 (20H, m), 7.69 (2H, d, J = 8 Hz), 7.99 (1H, s), 8.01 (2H, d, J = 7 Hz), 8.56 (1H, s), 8.99 (1H, br s). ¹³C-NMR (CDCl₃) δ c: 19.1, 20.5, 21.5, 26.7, 64.1, 68.4, 74.0, 74.6, 77.9, 86.57, 86.64, 123.4, 127.7, 127.8, 127.9, 128.1, 128.5, 128.8, 129.6, 129.9, 132.0, 132.3, 132.6, 132.7, 133.5, 135.4, 135.5, 136.8, 142.0, 144.7, 149.6, 151.2, 152.6, 164.5, 169.8. MS(FAB) m/z : 926 (M⁺+H).

(2) Synthesis of 3'-O-benzyl-5'-O-t-butylldiphenylsilyl-
4'-p-toluenesulfonyloxymethyl-N⁶-benzoyladenine
(Compound 41)

To a methyl alcohol solution (3.0 ml) of Compound 40
5 (167.9 mg, 0.182 mmol), potassium carbonate (15.0 mg, 0.109
mmol) was added at room temperature, and the mixture was
stirred for 15 minute at room temperature. Concentrated
hydrochloric acid was added to the reaction mixture to
neutralize it, whereafter the system was extracted 3 times
10 with methylene chloride. The organic phase was washed with
a saturated sodium chloride solution, and then dried over
sodium sulfate. The solvents were distilled off under
reduced pressure, and the resulting crude product was
purified by silica gel column chromatography (CHCl₃-MeOH,
15 30:1) to obtain a white powder, Compound 41 (140.5 mg, 0.160
mmol, 88%).
m.p. 82-83°C (AcOEt-hexane). $[\alpha]_D^{25} - 6.02^\circ$ (c = 0.96, CHCl₃).
IR ν max (KBr) : 3306, 3066, 2935, 2859, 1701, 1611 cm⁻¹.
¹H-NMR (CDCl₃) δ : 0.98 (9H, s), 2.37 (3H, s), 3.76 (2H, s), 4.
20 39, 4.45 (1H, AB, J = 11 Hz), 4.54 (1H, d, J = 6 Hz), 4.67, 4.
76 (2H, AB, J = 11 Hz), 4.85 (1H, dd, J = 5, 6 Hz), 5.79 (1H, d,
J = 5 Hz), 7.20 - 7.58 (21H, m), 7.73 (2H, d, J = 8 Hz), 7.80
(1H, s), 7.96 (2H, d, J = 8 Hz), 8.49 (1H, s), 9.18 (1H, br s).
¹³C-NMR (CDCl₃) δ c: 19.1, 21.6, 26.8, 64.4, 68.9, 74.1, 74.6,
25 79.2, 86.8, 89.8, 123.1, 127.7, 127.8, 128.0, 128.2, 128.4, 1
28.6, 128.8, 129.7, 130.0, 132.1, 132.5, 132.6, 132.8, 133.4,
135.4, 135.5, 136.8, 142.1, 144.8, 149.4, 152.3, 164.5.

(3) Synthesis of 3'-O-benzyl-5'-O-t-butylldiphenylsilyl-

2'-O,4'-C-methylene-N⁶-benzyladenosine (Compound 42)

In a stream of nitrogen, sodium
bis(trimethylsilyl)amide (1.0 M in THF, 0.58 ml, 0.572 mmol)
was added to a tetrahydrofuran solution (8.0 ml) of Compound
5 41 (210.5 mg, 0.238 mmol) at room temperature, and the
mixture was stirred for 3 hours at room temperature. A
saturated sodium bicarbonate solution was added to the
reaction mixture, and then the system was extracted 3 times
with methylene chloride. The organic phase was washed with
10 a saturated sodium chloride solution, and then dried over
sodium sulfate. The solvents were distilled off under
reduced pressure, and the resulting crude product was
purified by silica gel column chromatography (CHCl₃-MeOH,
30:1) to obtain a white powder, Compound 42 (169.5 mg, 0.238
15 mmol, quant.).

mp. 80- 81°C. IR ν max (KBr): 3259, 3064, 2932, 2858, 1703,
1607 cm⁻¹.

¹H-NMR(CDCl₃) δ : 1.07 (9H, s), 3.95, 4.10 (2H, AB, J = 8 Hz), 4.
02 (2H, d, J = 8 Hz), 4.56, 4.64 (2H, AB, J = 12 Hz), 4.26 (1H,
20 s), 4.86 (1H, s), 6.14 (1H, s), 7.26 - 7.70 (18H, m), 8.04 (2
H, d, J = 7 Hz), 8.22 (1H, s), 8.78 (1H, s), 9.18 (1H, brs).

¹³C-NMR(CDCl₃) δ c: 19.2, 26.5, 26.8, 29.7, 59.2, 72.4, 72.6, 7
6.5, 76.8, 86.7, 88.6, 123.4, 127.7, 127.8, 127.9, 128.1,
128.4, 128.8, 129.5, 130.0, 132.4, 132.5, 132.8, 133.5, 134.8,
25 135.2, 135.5, 135.6, 136.8, 140.4, 152.7.

(4) Synthesis of 3'-O-benzyl-2'-O,4'-C-methylene-N⁶-
benzoyladenosine (Compound 43)

Tetrabutylammonium fluoride (1.0 M in THF, 1.0 ml,

1.0 mmol) was added, at room temperature, to a tetrahydrofuran solution (7.0 ml) of Compound 42 (173.6 mg, 0.244 mmol), and the mixture was stirred for 25 minutes at room temperature. The reaction mixture was distilled under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl₃-MeOH, 15:1) to obtain a white powder, Compound 43 (115.4 mg, 0.244 mmol, quant.).

mp. 154 - 155°C (Et₂O). IR ν max(KBr): 3339, 2944, 1701, 1611 cm⁻¹.

¹H-NMR(CDCl₃) δ : 3.91, 4.13 (2H, AB, J = 8 Hz), 3.93, 4.01 (2H, AB, J = 12 Hz), 4.38 (1H, s), 4.64 (1H, s), 4.85 (1H, s), 6.08 (1H, s), 7.29 (1H, s), 7.51 (2H, d, J = 8 Hz), 7.58 (1H, d, J = 7 Hz), 8.05 (2H, d, J = 7 Hz), 8.14 (1H, s), 8.75 (1H, s), 9.50 (1H, br s).

¹³C-NMR(CDCl₃) δ c: 57.1, 72.4, 77.0, 77.1, 86.9, 88.6, 122.9, 127.6, 128.0, 128.1, 128.4, 128.7, 132.8, 133.5, 136.9, 140.5, 149.8, 150.5, 152.8, 165.0.

[Example 5]

(1) Synthesis of 2'-O-acetyl-3'-O-benzyl-5'-O-t-butyldiphenylsilyl-4'-p-toluenesulfonyloxymethyl-N²-isobutyrylguanosine (Compound 44)

In a stream of nitrogen, a 1,2-dichloroethane solution (5.0 ml) of Compound 4 (250 mg, 0.336 mmol) and trimethylsilyltrifluoromethane sulfonate (6.7 μ l, 0.0336 mmol) were added, at room temperature, to 3TMS·G^{iBu} (146.8 mg, 0.336 mmol) prepared in accordance with the aforementioned reference 6). The mixture was heated under reflux for 15

hours. After a saturated sodium bicarbonate solution was added to the reaction mixture, the system was extracted 3 times with methylene chloride. The organic phase was washed with a saturated sodium chloride solution, and then dried
5 over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl₃-MeOH, 30:1) to obtain a white powder, Compound 44 (213.6 mg, 0.235 mmol, 70%).

10 m.p. 96-97°C (AcOEt-hexane). $[\alpha]_D^{24}$ -11.09° (c = 0.97, CHCl₃).

IR ν max (KBr): 3152, 3065, 2934, 1746, 1681, 1606 cm⁻¹.

¹H-NMR (CDCl₃) δ : 0.96 (9H, s), 1.10 (3H, d, J = 9 Hz), 1.13 (3H, d, J = 9 Hz), 1.98 (3H, s), 2.36 (3H, s), 2.48 (1H, m),
3.65, 3.72 (2H, AB, J = 11 Hz), 4.23, 4.43 (2H, AB, J = 11 Hz),
15 4.47 (2H, s), 4.63 (1H, d, J = 6 Hz), 5.74 (1H, t, J = 6 Hz),
5.96 (1H, d, J = 6 Hz), 7.14 - 7.68 (20H, m), 9.15 (1H, s), 12.
20 (1H, s).

¹³C-NMR(CDCl₃) δ c: 19.1, 19.3, 19.4, 20.8, 21.9, 27.0, 27.2, 36.
5, 64.5, 68.9, 74.4, 74.9, 76.7, 86.1, 86.7, 122.0, 127.6, 12
20 7.7, 127.9, 128.1, 128.3, 128.4, 128.8, 130.1, 130.4, 132.3,
132.7, 132.9, 135.7, 135.8, 137.3, 137.8, 145.2, 147.8, 148.5,
156.2, 170.2, 178.8.

(2) Synthesis of 3'-O-benzyl-5'-O-t-butylidiphenylsilyl-
4'-p-toluenesulfonyloxymethyl-N²-isobutyrylguanosine
25 (Compound 45)

To a methyl alcohol solution (3.0 ml) of Compound 44 (137.0 mg, 0.151 mmol), potassium carbonate (15.8 mg, 0.113 mmol) was added at room temperature, and the mixture was

stirred for 45 minutes at room temperature. Concentrated hydrochloric acid was added to the reaction mixture to neutralize it, whereafter the system was extracted 3 times with methylene chloride. The organic phase was washed with
5 a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl₃-MeOH, 30:1) to obtain a white powder, Compound 45 (83.4 mg, 0.097
10 mmol, 64%).
mp. 102-103°C (AcOEt-hexane). $[\alpha]_D^{25} - 2.00^\circ$ (c = 0.40, CHCl₃). IR ν max(KBr): 3166, 2932, 1684, 1607 cm⁻¹.
¹H-NMR (CDCl₃) δ : 0.90 (9H, s), 1.09 (3H, d, J = 7 Hz), 1.13 (3H, d, J = 7 Hz), 2.30 (1H, m), 2.37 (3H, s), 3.71, 3.76 (2H, AB, J = 11 Hz), 4.32, 4.48 (2H, AB, J = 11 Hz), 4.35 (1H, d, J = 6 Hz), 4.63, 4.90 (2H, AB, J = 12 Hz), 4.96 (1H, t, J = 6 Hz), 5.67 (1H, d, J = 7 Hz), 7.17 - 7.71 (20H, m), 8.82 (1H, s),
15 12.05 (1H, br s).
¹³C-NMR(CDCl₃) δ c: 18.7, 19.0, 21.6, 26.5, 36.2, 63.5, 69.1,
20 73.7, 74.3, 78.8, 86.2, 89.5, 127.7, 127.8, 128.0, 128.1, 128.5, 129.7, 130.0, 132.0, 132.6, 132.7, 135.3, 135.4, 137.4, 138.2, 144.8, 146.9, 155.5, 178.5.
(3) Synthesis of 3'-O-benzyl-5'-O-t-butyldiphenylsilyl-2'-O,4'-C-methylene-N²-isobutyrylguanosine (Compound
25 46)
In a stream of nitrogen, sodium bis(trimethylsilyl)amide (1.0 M in THF, 0.31 ml, 0.315 mmol)

was added to a tetrahydrofuran solution (3.0 ml) of Compound 45 (92.1 mg, 0.102 mmol) at room temperature, and the mixture was stirred for 3 hours at room temperature. A saturated sodium bicarbonate solution was added to the reaction mixture, and then the system was extracted 3 times with methylene chloride. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl₃-MeOH, 25:1) to obtain a white powder, Compound 46 (31.4 mg, 0.160 mmol, 44%).

mp. 99-100°C. IR ν max(KBr): 3162, 3068, 2932, 1683, 1610 cm⁻¹.

¹H-NMR(CDCl₃) δ : 1.06 (9H, s), 1.25 (3H, d, J = 7 Hz), 1.27 (3H, d, J = 7 Hz), 2.64 (1H, m), 3.83, 4.01 (2H, AB, J = 8 Hz), 3.97 (2H, d, J = 7 Hz), 4.18 (1H, s), 4.51 (1H, s), 4.54 (2H, d, J = 2 Hz), 5.77 (1H, s), 7.17-7.42 (5H, m), 7.64 - 7.72 (10H, m), 7.84 (1H, s), 9.03 (1H, s), 12.08 (1H, br s).

¹³C-NMR(CDCl₃) δ c: 18.9, 19.0, 19.1, 26.5, 26.7, 36.4, 59.1, 72.4, 72.5, 76.8, 77.5, 86.3, 88.3, 121.7, 127.6, 127.7, 127.8, 127.9, 128.1, 128.4, 129.6, 130.0, 132.36, 132.42, 134.8, 135.45, 135.54, 135.8, 136.8, 146.8, 147.7, 155.4, 178.6.

(4) Synthesis of 3'-O-benzyl-2'-O,4'-C-methylene-N²-isobutyrylguanosine (Compound 47)

Tetrabutylammonium fluoride (1.0 M in THF, 0.90 ml, 0.90 mmol) was added, at room temperature, to a tetrahydrofuran solution (3.0 ml) of Compound 46 (41.3 mg, 0.060 mmol), and the mixture was stirred for 1 hour at room

temperature. The reaction mixture was distilled under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOH-EtOH, 20:1) to obtain a white powder, Compound 47 (27.1 mg, 0.060 mmol, quant.).


mp. 228 - 229°C(Et₂O). $[\alpha]_D^{25} + 32.90^\circ$ (c = 0.875, CHCl₃).

IR ν max (KBr) : 3162, 2934, 1683, 1608 cm⁻¹.

¹H-NMR (CDCl₃) δ : 1.24 (3H, d, J = 7 Hz), 1.26 (3H, d, J = 7 Hz), 2.76 (1H, m), 3.83, 4.03 (2H, AB, J = 8 Hz), 3.92, 4.02 (2H, AB, J = 13 Hz), 4.33 (1H, s), 4.55 (1H, s), 4.62 (2H, s), 5.80 (1H, s), 7.25 (5H, s), 7.91 (1H, s), 9.85 (1H, s), 12.05 (1H, s).


¹³C-NMR (CDCl₃) δ c: 19.19, 19.25, 36.4, 57.4, 72.5, 77.0, 77.5, 86.5, 88.8, 121.0, 127.8, 128.1, 128.2, 128.3, 128.4, 128.6, 137.1, 137.5, 147.5, 148.2, 155.7, 179.9.

[Example 6] Synthesis of oligonucleotide analogue



25

5'-GCGXTTITGCT-3'	(XT5)
5'-GCGTTXTTIGCT-3'	(T2XT3)
5'-GCGTTTXXTGCT-3'	(T3XT2)
5'-GCGTTTTXXGCT-3'	(T5X)
5'-GCGXXTTTIGCT-3'	(X2T4)
5'-GCGTTXXTTGCT-3'	(T2X2T2)
5'-GCGTTTTXXGCT-3'	(T4X2)
5'-GCGXXXXXXGCT-3'	(X6)
5'-GTTTTTTTTXXC-3'	(X2)



(1) 3'-O-[2-cyanoethoxy(diisopropylamino)phosphino]-5'-O-(4,4'-dimethoxytrityl)-2'-O,4'-methanouridine
(Compound 21)

Compound 8 (200 mg, 0.31 mmol) and

5 diisopropylammonium tetrazolide (39.6 mg, 0.23 mmol) were subjected to azeotropy with anhydrous CH₃CN three times, and then the system was converted into an anhydrous CH₃CN-anhydrous THF solution (3:1, 4 ml). In a stream of nitrogen, 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite
10 (0.12 ml, 0.37 mmol) was added, and the mixture was stirred for 90 minutes at room temperature. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt:hexane:Et₃N = 75:25:1). Then, the
15 purified product was reprecipitated from AcOEt-hexane to obtain an amidite compound 21 (181 mg, 0.25 mmol, 81%).
m.p. 71-74°C (AcOEt-hexane).

³¹P-NMR (CDCl₃): δ 149.6, 149.5, 149.4, 149.3, 149.2.

(2) General synthesis of oligonucleotide analogues

20 The synthesis of an oligomer was performed by means of Pharmacia's DNA synthesizer, Gene Assembler Plus, on a 0.2 μmol scale. The concentrations of solvents, reagents, and phosphoramidite were the same as for the synthesis of natural DNA. A DMTr group of 5'-O-DMTr-thymidine (0.2 μmol)
25 having a 3'-hydroxyl group bound to a CPG support was deprotected with trichloroacetic acid. On its 5'-hydroxyl group, condensation reaction was repeated using an amidite comprising four nucleic acid bases for natural DNA synthesis

and Compound 21 to synthesize oligonucleotide analogues of respective sequences. The synthetic cycle was as follows:

Synthetic cycle (0.2 μ mol scale)

- 1) Detritylation 1% CCl_3COOH in $\text{CH}_2\text{ClCH}_2\text{Cl}$, 6 sec
- 5 2) Coupling 0.1 M phosphoramidite (25 equiv.),
0.5 M 1H-tetrazole (500 equiv.) in MeCN,
2 min
- 3) Capping 3% 4-(dimethylamino)pyridine, 10% Ac_2O ,
in MeCN, 18 sec
- 10 4) Oxidation 0.01 M I_2 in 2,4,6-collidine/ H_2O /MeCN
(1:5:11), 6 sec

The synthesized oligomer was cleaved from the support by treatment with concentrated aqueous ammonia in the customary manner. At the same time, the protective
15 cyanoethyl group was detached from the phosphorus atom, and the protective groups for the adenine, guanine and cytosine were also removed.

The resulting 5'-O-dimethoxytritylated oligonucleotide analogue was rid of the DMTr group by use of
20 5 ml trifluoroacetic acid on a reversed phase chromatographic column (Millipore, Oligo-PakTMSP), and further purified to obtain the desired oligonucleotide analogue.

In accordance with the foregoing method for general
25 synthesis, the following oligonucleotide analogues were synthesized:

(2) 5'-GCGXTTTTGTGCT-3' (XT5)

Yield 0.06 μ mol (30% yield)

- 662960"2E908E50
- (3) 5'-GCGTTXTTTTGCT-3' (T2XT3)
Yield 0.05 μ mol (25% yield)
- (4) 5'-GCGTTTXXTTTGCT-3' (T3XT2)
Yield 0.03 μ mol (15% yield)
- 5 (5) 5'-GCGTTTTTTXGCT-3' (T5X)
Yield 0.06 μ mol (30% yield)
- (6) 5'-GCGXXTTTTTGCT-3' (X2T4)
Yield 0.06 μ mol (30% yield)
- (7) 5'-GCGTTXXTTTGCT-3' (T2X2T2)
10 Yield 0.05 μ mol (25% yield)
- (8) 5'-GCGTTTTXXGCT-3' (T4X2)
Yield 0.06 μ mol (30% yield)
- (9) 5'-GCGXXXXXXGCT-3' (X6)
Yield 0.06 μ mol (30% yield)
- 15 (10) 5'-GTTTTTTTTTXXC-3' (X2)
Yield 0.07 μ mol (35% yield)

[Experimental Example 1] Measurement of melting
temperature (T_m)

20 The melting temperatures (T_m 's) of annealing products
between antisense strands, which were the various
oligonucleotide analogues synthesized in Example 2, and
natural DNA- or RNA-based sense strands were measured to
investigate the hybridizing ability of the oligonucleotide
25 analogues of the present invention for complementary DNA and
RNA.

Each sample solution (500 μ L) with end concentrations
of 100 mM NaCl, 10 mM sodium phosphate buffer (pH 7.2), 4 μ M

antisense strand, and 4 μ M sense strand, respectively, was bathed in boiling water, and slowly cooled to room temperature over the course of 10 hours. The sample solution was gradually cooled to 5°C, kept at 5°C for a
5 further period of 20 minutes, and then started to be measured, with a stream of nitrogen being passed through a cell chamber of a spectrophotometer (UV-2100PC, Shimadzu) for prevention of moisture condensation. The sample temperature was raised at a rate of 0.2°C/minute until 90°C,
10 and the ultraviolet absorption at 260 nm was measured at intervals of 0.1°C. To prevent changes in the sample concentration with increases in the temperature, the cell was provided with a closure, and a drop of a mineral oil was applied onto the surface of the sample solution during
15 measurement.

The results are shown in the following table.

Table 1 Melting Temperatures (T_m's) of Antisense Oligonucleotide Analogues for Complementary DNA and RNA

Antisense molecule	T _m for complementary DNA ^{a)} (ΔT _m /mod.)	T _m for complementary RNA ^{b)} (ΔT _m /mod.)
5'-GCGTTTTTTGCT-3' (natural)	47°C	45°C
5'-GCGXTTTTTGCT-3' (XT5)	50°C (+3°C)	49°C (+4°C)
5'-GCGTTXTTTGCT-3' (T2XT3)	49°C (+2°C)	49°C (+4°C)
5'-GCGTTTXTTGCT-3' (T3XT2)	49°C (+2°C)	50°C (+5°C)
5'-GCGTTTTTXGCT-3' (T5X)	52°C (+4°C)	51°C (+6°C)
5'-GCGXXTTTTGCT-3' (X2T4)	51°C (+2°C)	53°C (+4°C)
5'-GCGTTXXTTGCT-3' (T2X2T2)	49°C (+1°C)	53°C (+4°C)
5'-GCGTTTTXXGCT-3' (T4X2)	54°C (+3.5°C)	55°C (+5°C)
5'-GCGXXXXXXGCT-3' (X6)	58°C (+1.8°C)	71°C (+4.3°C)

5 a): 3'-CGCAAAAACGA-5'. b): 3'-r(CGCAAAAACGA).

As shown in the table, in the case of the oligomer having one or two units (X) of the nucleoside analogue of the present invention (general formula (Ia)) introduced into
 10 a natural DNA strand, the ability to hybridize with the

complementary DNA oligomer, evaluated by the T_m , rose by 2 to 7 degrees (about 2 degrees per modified residue) as compared with the natural strand. With the oligomer having all T's substituted by X's (X6), the increase in the ability
5 was as high as 11 degrees. When the ability to hybridize with complementary RNA was evaluated, the oligomer incorporating one or two X's had an increase in T_m of 4 - 10 degrees (4 to 6 degrees per modified residue) over the natural strand. In the case of X6, the ability to hybridize
10 with complementary RNA was further enhanced, showing an increase in T_m of more than 25 degrees (4 degrees per modified residue). There have been no examples of analogues undergoing such increases in T_m as compared with natural strands, and the affinity of the claimed oligomer was higher
15 for RNA than for DNA. These facts mean that the oligonucleotide analogue composed of the bicyclicoligonucleoside analogue of the present invention has extremely high performance as an antisense molecule, and is useful as a material for pharmaceuticals.

20 [Experimental Example 2] Measurement of nuclease resistance

A buffer solution (0.003 U/ml, 400 μ l) of a snake venom phosphodiesterase was mixed with a buffer solution (10 μ M, 400 μ l) of the oligonucleotide held at 37°C for 15
25 minutes. The mixed solution was placed in a quartz cell (800 μ l) kept at 37°C, and increases in the ultraviolet absorption (260 nm) due to the decomposition of the oligonucleotide were measured over time by means of SHIMADZU

UV-2100PC. The buffer used comprised 0.1 M Tris-HCl (pH 8.6), 0.1 M NaCl, and 14 mM MgCl₂, and was sufficiently degassed before measurement.

Measurement of half-life ($t_{1/2}$):

5 A calculation was made of the average of the values of the UV absorption measured at the start of measurement ($t=0$) and that measured at the time when no increase in this parameter was noted. The time corresponding to this average was designated as the half-life ($t_{1/2}$).

10

Oligonucleotide sequence	$t_{1/2}$ (seconds)
5'-GTTTTTTTTTTC-3' (natural type)	260
5'-GTTTTTTTTT-XX-C-3' (X2)	850

15

Charts showing the time course of the ultraviolet absorption are presented as Fig. 1 (natural strand) and Fig. 2 (X2). The ultraviolet absorption reached a plateau in about 30 minutes for the natural strand, and about 90 minutes for X2, after initiation of the enzyme reaction.

20

INDUSTRIAL APPLICABILITY

The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.

25

Sequence Listing

Name of the applicant: Takeshi Imanishi

Title of the invention: Novel bicyclonucleoside and
oligonucleotide analogue

5 Reference No.:

Application No.:

Date of application: March , 1998

Priority No.: JPA 53409/97

Priority date: March 7, 1997

10 Number of sequences: 11

Seq. ID No.: 1

Length of sequence: 12

Type of sequence: Nucleotide

15 Number of strands: Single stranded

Topology: Linear

Sequence: 5'-GCGTTTTTTTGCT-3'

Seq. ID No.: 2

20 Length of sequence: 12

Type of sequence: Nucleotide, nucleotide analogue

Number of strands: Single stranded

Topology: Linear

Sequence: 5'-GCGXTTTTTTGCT-3'

25

Seq. ID No.: 3

Length of sequence: 12

Type of sequence: Nucleotide, nucleotide analogue

Number of strands: Single stranded

Topology: Linear

Sequence: 5'-GCGTTXXTTGCT-3'

5 Seq. ID No.: 8

Length of sequence: 12

Type of sequence: Nucleotide, nucleotide analogue

Number of strands: Single stranded

Topology: Linear

10 Sequence: 5'-GCGTTTTXXGCT-3'

Seq. ID No.: 9

Length of sequence: 12

Type of sequence: Nucleotide, nucleotide analogue

15 Number of strands: Single stranded

Topology: Linear

Sequence: 5'-GCGXXXXXXGCT-3'

Seq. ID No.: 10

20 Length of sequence: 13

Type of sequence: Nucleotide, nucleotide analogue

Number of strands: Single stranded

Topology: Linear

Sequence: 5'-GTTTTTTTTTTTC-3'

25

Seq. ID No.: 11


Length of sequence: 13

Type of sequence: Nucleotide, nucleotide analogue

[illegible][illegible][illegible]

CLAIMS

1. A nucleoside analogue of the following general formula (I)



(I)


where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, and X and Y are identical or different, and each represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aralkyl group, an aryl group, an acyl group, or a silyl group,

or an amidite derivative thereof.

2. A nucleoside analogue as claimed in claim 1, wherein X and Y each represent a hydrogen atom.

3. A mononucleoside amidite derivative as claimed in claim 1, wherein X is 4,4-dimethoxytrityl (DMTr), and Y is a 2-cyanoethoxy(diisopropylamino)phosphino group (amidite group).


4. An oligonucleotide or polynucleotide analogue having one or more structures of the general formula (Ia)



(Ia)

where B is a pyrimidine or purine nucleic acid base, or an analogue thereof.

5. An oligonucleotide or polynucleotide analogue of the general formula (II)



(II)

where B¹ and B are identical or different, and each represent a pyrimidine or purine nucleic acid base, or an analogue thereof, R is a hydrogen atom, a hydroxyl group, a halogen atom, or an alkoxy group, W¹ and W² are identical or different, and each represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aralkyl group, an aryl group, an acyl group, a silyl group, a phosphoric acid residue, a naturally


occurring nucleoside or a synthetic nucleoside bound via a phosphodiester bond, or an oligonucleotide or polynucleotide containing the nucleoside, n^1 's or n^2 's are identical or different, and each denote an integer of 0 to 50, provided that n^1 's or n^2 's are not zero at the same time, and that not all of n^2 's are zero at the same time, n^3 denotes an integer of 1 to 50, provided that when n^1 and/or n^2 are or is 2 or more, B^1 and B need not be identical, and R 's need not be identical.

NOVEL BICYCLONUCLEOSIDE AND OLIGONUCLEOTIDE ANALOGUE

ABSTRACT

An oligo- or polynucleotide analogue having one or more structures of the general formula

5



10

(I)

where B is a pyrimidine or purine nucleic acid base,
or an analogue thereof,

15 is disclosed. The use of this analogue provides an
oligonucleotide analogue antisense molecule, which is
minimally hydrolyzable with an enzyme in vivo, has a high
sense strand binding ability, and is easily synthesized.

662060" BE208E60

09/380638





Fig. 1



x-197 305
pgc-1-1208 05

Combined Declaration for Patent Application and Power of Attorney

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
NOVEL BICYCLONUCLEOSIDE AND OLIGONUCLEOTIDE ANALOGUE

the specification of which (check one)

☐ is attached hereto;

☐ was filed in the United States under 35 U.S.C. §111 on _____, as
USSN _____*; or

☒ was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/JP98/00945; filed March 9, 1998
entry requested on _____*; national stage application received
USSN _____*; §371/§102(e) date _____* (*if known),

and was amended on _____ (if applicable).

(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119, 365 of any prior foreign application(s) for patent or inventor's certificate, or prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked and have also identified below any such application having a filing date before that of the application on which priority is claimed:

<u>53409/1997</u>	<u>Japan</u>	<u>7/3/1997</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO
_____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO
_____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO

I hereby claim the benefit under 35 U.S.C. § 120 of any prior U.S. non-provisional Application(s) or prior PCT Application(s) designating the U.S. listed below, or under § 119(e) of any prior U.S. provisional applications listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information as defined in 37 C.F.R. §1.56(a) which occurred between the filing date of the prior application and the national filing date of this application:

_____ (Application Serial No.)	_____ (Day Month Year Filed)	_____ (Status: patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Day Month Year Filed)	_____ (Status: patented, pending, abandoned)

I hereby appoint the following attorneys, with full power of substitution, association, and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

7 SHERIDAN NEIMARK, REG. NO. 20,520 - ROGER L. BROWDY, REG. NO. 25,618 - ANNE M. KORNBAU, REG. NO. 25,884
NORMAN J. LATKER, REG. NO. 19,963 - IVER P. COOPER, REG. NO. 28,005 - ALLEN C. YUN, REG. NO. 37,971*
NICK S. BROMER, REG. NO. 33,478 - * Patent Agent

ADDRESS ALL CORRESPONDENCE TO
BROWDY AND NEIMARK, P.L.L.C.
419 Seventh Street, N.W.
Washington, D.C. 20004

DIRECT ALL TELEPHONE CALLS TO:
BROWDY AND NEIMARK
(202) 628-5197

The undersigned hereby authorizes the U.S. Attorneys or Agents named herein to accept and follow instructions from YUASA and HARA as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorney or Agent and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents named herein will be so notified by the undersigned.

7/2

Page 2 of 2

Atty.Docket:

Title:

U.S. Application filed _____, Serial No. _____

PCT Application filed _____, Serial No. _____

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR <u>Takeshi IMANISHI</u>		INVENTOR'S SIGNATURE <u>Takeshi Imanishi</u>	DATE July 30 1999
RESIDENCE <u>Nara-ken, Japan JPX</u>		CITIZENSHIP Japanese	
POST OFFICE ADDRESS 2-18, Chiyogaoka 2-chome, Nara-shi, Nara 631-0045 Japan			
FULL NAME OF SECOND JOINT INVENTOR <u>Satoshi OBIKA</u>		INVENTOR'S SIGNATURE <u>Satoshi Obika</u>	DATE July 30 1999
RESIDENCE <u>Osaka, Japan JPX</u>		CITIZENSHIP Japanese	
POST OFFICE ADDRESS 2034, Yonbancho, Hiyoshidai, Takatsuki-shi, Osaka 569-1022 Japan			
FULL NAME OF THIRD JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FOURTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.